

Financial news for ALXN dated on 2020-06-08: 4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

Financial news for ALXN dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for ALXN dated on 2020-06-01: Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$147

Financial news for ALXN dated on 2020-05-29: SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$159

Financial news for ALXN dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for ALXN dated on 2020-05-20: Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.

Financial news for ALXN dated on 2020-05-14: Alexion Highlights Upcoming Data Presentations At European Hematology Association Jun. 11-14

Financial news for ALXN dated on 2020-05-12: Why Alexion's Stock Is Trading Higher Today

Financial news for ALXN dated on 2020-05-12: Alexion Pharmaceuticals shares are trading higher on a report that Elliott Advisors sent a letter to the company seeking an immediate expiration of sales.

Financial news for ALXN dated on 2020-05-12: UPDATE: Elliott's Letter To Alexion Board

Financial news for ALXN dated on 2020-05-12: Elliott Advisors Says Portola's 'Lack Of Obvious Strategic Fit' With Alexion Is What Drove 'Bulk Of The Market's Negative Reaction, In Our View'

Financial news for ALXN dated on 2020-05-12: Portola Pharma Shares Volatile, Very Slightly Lower, Following Letter From Elliott Advisors To Alexion Criticizing Deal With Co.

Financial news for ALXN dated on 2020-05-12: Watching Alexion Pharma Shares Premarket Amid Report Elliott Advisors Sent Letter To Co., Seeking Immediate Exploration Of Sale

Financial news for ALXN dated on 2020-05-08: 5 Biopharmas Where BofA Would Put Its Money To Work

Financial news for ALXN dated on 2020-05-08: SunTrust Robinson Humphrey Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to \$135

Financial news for ALXN dated on 2020-05-07: BMO Capital Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$142

Financial news for ALXN dated on 2020-05-07: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$156

Financial news for ALXN dated on 2020-05-07: SVB Leerink Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$150

Financial news for ALXN dated on 2020-05-07: Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Raises Price Target to \$120

Financial news for ALXN dated on 2020-05-06: CFRA Reiterates Strong Buy on Alexion Pharmaceuticals, Lowers Price Target of \$159

Financial news for ALXN dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for ALXN dated on 2020-05-06: Alexion Cuts FY20 Adj. EPS Guidance From \$10.65-\$10.85 To \$10.45-\$10.75 vs \$11.01 Est., Cuts Sales Guidance From \$5.50B-\$5.56B To \$5.23B-\$5.33B vs \$5.6B Est.

Financial news for ALXN dated on 2020-05-06: Alexion Pharmaceuticals Q1 Adj. EPS \$3.220 Beats \$2.710 Estimate, Sales \$1.445B Beat \$1.360B Estimate

Financial news for ALXN dated on 2020-05-06: 70 Biggest Movers From Yesterday

Financial news for ALXN dated on 2020-05-06: Earnings Scheduled For May 6, 2020

Financial news for ALXN dated on 2020-05-05: Mid-Afternoon Market Update: NASDAQ Surges More Than 2%; Itron Shares Slide

Financial news for ALXN dated on 2020-05-05: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ALXN dated on 2020-05-05: Mid-Day Market Update: Crude Oil Jumps 19%; Fulgent Genetics Shares Plunge Following Q1 Earnings

Financial news for ALXN dated on 2020-05-05: Why Alexion's Stock Is Trading Lower Today

Financial news for ALXN dated on 2020-05-05: Mid-Morning Market Update: Markets Open Higher; Sysco Misses Q3 Views

Financial news for ALXN dated on 2020-05-05: Alexion Pharmaceuticals shares are trading lower after the company reported the purchase of Portola Pharma for \$18 per share in cash.

Financial news for ALXN dated on 2020-05-05: What You Should Know About Alexion's \$1.4B Proposed Buyout Of Portola Pharma

Financial news for ALXN dated on 2020-05-05: Alexion Reports Purchase Of Portola Pharma For \$18/Share In Cash

Financial news for ALXN dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ALXN dated on 2020-05-01: UPDATE: Alexion Sees European Commission Decision In Jun. 2020

Financial news for ALXN dated on 2020-05-01: Alexion Pharma Reports Receives CHMP Positive Opinion For ULTOMIRIS In Atypical Hemolytic Uremic Syndrome

Financial news for ALXN dated on 2020-04-28: Alexion Pharmaceuticals shares are trading lower. Cantor Fitzgerald initiated coverage with a Neutral rating.

Financial news for ALXN dated on 2020-04-28: Cantor Fitzgerald Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces Price Target to \$121

Financial news for ALXN dated on 2020-04-20: Why Alexion's Stock Is Trading Higher Today

Financial news for ALXN dated on 2020-04-20: Alexion Pharmaceuticals shares are trading higher after the company announced plans to initiate Phase 3 study of ULTOMIRIS in hospitalized patients with severe COVID-19.

Financial news for ALXN dated on 2020-04-20: Alexion Pharma Outlines Plans To Initiate Phase 3 Study Of ULTOMIRIS In Hospitalized Patients With Severe Coronavirus Infection

Financial news for ALXN dated on 2020-04-17: JP Morgan Maintains Overweight on Alexion Pharmaceuticals, Lowers Price Target to \$163

Financial news for ALXN dated on 2020-04-17: Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.

Financial news for ALXN dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Lowers Price Target to \$116

Financial news for ALXN dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for ALXN dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for ALXN dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US

hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for ALXN dated on 2020-04-01: Stealth BioTherapeutics Says Recognized \$21.1M In Revenue Associated With Alexion Arrangement; Alexion Terminated Agreement

Financial news for ALXN dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for ALXN dated on 2020-03-21: Notable Insider Buys In The Past Week: AutoZone, Exxon, Dell And More

Financial news for ALXN dated on 2020-03-17: Oppenheimer Downgrades Alexion Pharmaceuticals to Perform

Financial news for ALXN dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for ALXN dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for ALXN dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for ALXN dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for ALXN dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for ALXN dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for ALXN dated on 2020-03-06: Stocks That Hit 52-Week Lows On Friday

Financial news for ALXN dated on 2020-03-05: Benzinga's Top Upgrades, Downgrades For March 5, 2020

Financial news for ALXN dated on 2020-03-05: 10 Biggest Price Target Changes For Thursday

Financial news for ALXN dated on 2020-03-05: B of A Securities Downgrades Alexion Pharmaceuticals to Neutral, Lowers Price Target to \$110

Financial news for ALXN dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for ALXN dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for ALXN dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for ALXN dated on 2020-02-25: Shares of several healthcare companies are trading lower as markets fall amid the continued spread of the coronavirus, which has raised concerns of a global economic slowdown, impacting stocks across sectors.

Financial news for ALXN dated on 2020-02-03: Nomura Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to \$133

Financial news for ALXN dated on 2020-01-31: RBC Capital Reinstates Outperform on Alexion Pharmaceuticals, Announces \$135 Price Target

Financial news for ALXN dated on 2020-01-31: Baird Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$140

Financial news for ALXN dated on 2020-01-31: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$159

Financial news for ALXN dated on 2020-01-30: Recap: Alexion Pharmaceuticals Q4 Earnings

Financial news for ALXN dated on 2020-01-30: The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance

Financial news for ALXN dated on 2020-01-30: Alexion Pharmaceuticals shares are

trading lower after the company issued FY20 EPS guidance below analyst estimates.

Financial news for ALXN dated on 2020-01-30: Alexion Sees FY20 Adj. EPS \$10.65-\$10.85 vs \$11.37 est, Sales \$5.5B-\$5.56B vs \$5.64B

Financial news for ALXN dated on 2020-01-30: Alexion Pharmaceuticals Q4 Adj. EPS \$2.71 Beats \$2.58 Estimate, Sales \$1.384B Beat \$1.3B Estimate

Financial news for ALXN dated on 2020-01-30: Earnings Scheduled For January 30, 2020

Financial news for ALXN dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for ALXN dated on 2020-01-17: Morgan Stanley Maintains Equal-Weight on Alexion Pharmaceuticals, Raises Price Target to \$131

Financial news for ALXN dated on 2020-01-10: A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations

Financial news for ALXN dated on 2020-01-08: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$161

Financial news for ALXN dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chugai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for ALXN dated on 2020-01-07: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALXN dated on 2019-12-19: Billion Shareholders Approve Agreement To Be Acquired By Alexion

Financial news for ALXN dated on 2019-12-17: UPDATE: Morgan Stanley On Alexion Pharmaceuticals Continues 'but we also believe mgt.'s organic plan to drive pipeline expansion is unlikely to close this gap in the near-term. Inorganic action remains the biggest risk to our EW'

Financial news for ALXN dated on 2019-12-17: UPDATE: Morgan Stanley Downgrades Alexion Pharmaceuticals To Equal-Weight, Lowers Target From \$170 To \$128 Notes 'We continue to believe Alexion represents one of the most significant disconnects between intrinsic and current value'

Financial news for ALXN dated on 2019-12-17: Benzinga's Top Upgrades, Downgrades For December 17, 2019

Financial news for ALXN dated on 2019-12-17: Morgan Stanley Downgrades Alexion Pharmaceuticals to Equal-Weight

Financial news for ALXN dated on 2019-12-09: Elliott Advisors Issues Statement On Alexion, Confirms Fund Had Multi-Year, Constructive, Private Engagement With Co., Calls Co. 'significantly undervalued by the market'

Financial news for ALXN dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Corveio Awaits Adcom Ruling

Financial news for ALXN dated on 2019-12-06: Alexion Pharmaceuticals shares are trading higher after the company announced it will not pursue a proactive sale process.

Financial news for ALXN dated on 2019-12-06: Alexion Shares Resume Trade, Up 4%

Financial news for ALXN dated on 2019-12-06: Alexion Shares To Resume Trade At 9 a.m. EST

Financial news for ALXN dated on 2019-12-06: Alexion Says Board Has Unanimously Decided That Conducting A Proactive Sale Process Would Not Be In Best Interest Of Shareholders

Financial news for ALXN dated on 2019-12-06: Alexion Shares Halted News Pending

Financial news for ALXN dated on 2019-12-06: Alexion Shares Halted News Pending

Financial news for ALXN dated on 2019-12-05: Alexion Pharmaceuticals shares are trading lower on seemingly no company-specific news.

Financial news for ALXN dated on 2019-11-22: Alexion Pharma Reports SOLIRIS Receives Approval In Japan

Financial news for ALXN dated on 2019-11-19: Alexion Pharmaceuticals shares are

trading higher on seemingly no company-specific news.

Financial news for ALXN dated on 2019-11-12: Benzinga's Top Upgrades, Downgrades For November 12, 2019

Financial news for ALXN dated on 2019-11-12: SunTrust Robinson Humphrey Initiates Coverage On Alexion Pharmaceuticals with Buy Rating, Announces \$125 Price Target

Financial news for ALXN dated on 2019-11-01: Alexion Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for ALXN dated on 2019-10-24: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$170

Financial news for ALXN dated on 2019-10-23: 14 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ALXN dated on 2019-10-23: Alexion Earlier Q3 Earnings Report Highlighted New \$1B Buyback Plan Announced In Oct. 2019

Financial news for ALXN dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for ALXN dated on 2019-10-23: Alexion Pharmaceuticals shares are trading higher after the company reported Q3 EPS and sales results up from last year. The company also raised FY19 EPS and sales guidance above analyst estimates.

Financial news for ALXN dated on 2019-10-23: Alexion Pharmaceuticals Raises FY19 Adj. EPS Guidance From \$9.65-\$9.85 To \$10.25-\$10.40 vs \$9.94 Est.; Raises Sales Guidance From \$4.75B-\$4.80B To \$4.86B-\$4.89B vs \$4.85B Est.

Financial news for ALXN dated on 2019-10-23: Alexion Pharmaceuticals Q3 Adj. EPS \$2.79 Up From \$2.02 YoY, Sales \$1.26B Up From \$1.027B YoY

Financial news for ALXN dated on 2019-10-21: 3 Stocks Moving On FDA Verdicts: Alexion, AstraZeneca, Foamix

Financial news for ALXN dated on 2019-10-20: The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Financial news for ALXN dated on 2019-10-17: The Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO

Financial news for ALXN dated on 2019-10-17: 54 Biggest Movers From Yesterday

Financial news for ALXN dated on 2019-10-16: Mid-Afternoon Market Update: Crude Oil Up 1%; Tech Data Shares Spike Higher

Financial news for ALXN dated on 2019-10-16: Alexion Pharma shares are trading lower after the company announced it will acquire Achillion Pharmaceuticals for \$6.30 per share in cash plus added contingent considerations for a total potential value of \$8.30 per share.

Financial news for ALXN dated on 2019-10-16: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ALXN dated on 2019-10-16: Mid-Day Market Update: Achillion Pharmaceuticals Jumps Following Acquisition News; Natera Shares Plunge

Financial news for ALXN dated on 2019-10-16: Mid-Morning Market Update: Markets Edge Lower; Bank of America Earnings Beat Expectations

Financial news for ALXN dated on 2019-10-16: 23 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ALXN dated on 2019-10-16: Alexion To Acquire Achillion Pharma For \$930M

Financial news for ALXN dated on 2019-10-16: Alexion Pharma Reports Purchase Of Achillion Pharma For Initial Value Of \$6.30/Share In Cash Plus Added Contingent Considerations For Total Potential Value Of \$8.30/Share

Financial news for ALXN dated on 2019-10-15: Alexion Pharmaceuticals shares are trading higher. Shares have continued to post gains since the company on Thursday reported a deal with Stealth Therapeutics for the option to co-develop late-stage therapy for mitochondrial disease.

Financial news for ALXN dated on 2019-10-14: Jon Najarian Sees Unusual Options

## Activity In Alexion And Apache

Financial news for ALXN dated on 2019-10-14: Alexion Pharmaceuticals shares are trading higher on continued momentum after the company reported a deal for option to co-develop the Mitochondrial disease. The company is set to receive an initial \$30 million for equity investment.

Financial news for ALXN dated on 2019-10-14: Alexion Pharmaceuticals Option Alert: Nov 15 \$105 Calls Sweep (2) near the Ask: 3475 @ \$3.5 vs 393 OI; Earnings 10/23 Before Open Ref=\$99.82

Financial news for ALXN dated on 2019-10-13: The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

Financial news for ALXN dated on 2019-10-11: 10 Biggest Price Target Changes For Friday

Financial news for ALXN dated on 2019-10-11: Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Lowers Price Target to \$170

Financial news for ALXN dated on 2019-10-10: Ra Pharma Stock Doubles On \$2.5B Buyout Deal With Belgian Biopharma UCB

Financial news for ALXN dated on 2019-10-10: Alexion, Stealth BioTherapeutics Report Deal For Option To Co-Develop, Commercialize Late-Stage Therapy For Mitochondrial Disease; Stealth Will Receive Initial \$30M Payment For Equity Investment

Financial news for ALXN dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for ALXN dated on 2019-09-26: Alexion Pharmaceuticals shares are trading lower despite William Blair initiating coverage on the company's stock with an Outperform rating and \$146 price target.

Financial news for ALXN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for ALXN dated on 2019-09-26: Benzinga's Top Upgrades, Downgrades For September 26, 2019

Financial news for ALXN dated on 2019-09-26: William Blair Initiates Coverage On Alexion Pharmaceuticals with Outperform Rating, Announces \$146 Price Target

Financial news for ALXN dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for ALXN dated on 2019-09-18: Alexion Pharmaceuticals shares are trading lower after the company announced there will be a CFO transition after the filing of Q3 results.

Financial news for ALXN dated on 2019-09-18: The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

Financial news for ALXN dated on 2019-09-17: Alexion Pharma Announces CFO Transition; Paul Clancy To Be Succeeded By Aradhana Sarin, M.D. After Filing Of Q3 Results

Financial news for ALXN dated on 2019-09-12: Benzinga's Top Upgrades, Downgrades For September 12, 2019

Financial news for ALXN dated on 2019-09-12: BMO Capital Initiates Coverage On Alexion Pharmaceuticals with Outperform Rating, Announces \$149 Price Target

Financial news for ALXN dated on 2019-09-09: Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis Investigational Medicine, Eidos to Receive a \$25M Upfront Payment and \$25M Equity Investment

Financial news for ALXN dated on 2019-09-06: Alexion Pharmaceuticals shares are trading higher after Credit Suisse maintained an Outperform rating on the company's stock.

Financial news for ALXN dated on 2019-09-06: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ALXN dated on 2019-09-06: Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Lowers Price Target to \$146

Financial news for ALXN dated on 2019-09-05: Alexion Says European Patent Office

Didn't Grant Soliris Patents; Co. To Appeal Decision

Financial news for ALXN dated on 2019-09-05: Shares of several healthcare companies are trading higher in sympathy with the overall market after the Chinese Minister of Commerce said the leaders of the U.S. and China are set to meet in Washington D.C in early October. Investors hope the meeting could bring the two countries closer to a trade deal.

Financial news for ALXN dated on 2019-09-04: Alexion Pharmaceuticals shares are trading higher in sympathy with the overall market after data from China eased concerns of global growth slowing. Tensions in Hong Kong are also easing on the withdrawal of the extradition bill. The protests are seen as a potential disruptor to global growth.

Financial news for ALXN dated on 2019-09-03: Alexion shares are trading lower on continued weakness after Amgen last week challenged patents for Soliris.

Financial news for ALXN dated on 2019-09-03: 65 Biggest Movers From Friday

Financial news for ALXN dated on 2019-08-30: 'Fast Money Halftime Report' Picks For August 30

Financial news for ALXN dated on 2019-08-30: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for ALXN dated on 2019-08-30: Alexion shares are trading lower after Amgen challenged patents for Soliris.

Financial news for ALXN dated on 2019-08-30: Alexion Pharmaceuticals, On Patent Challenge To Soliris, Says Will Defend Them In The Course Of The IPR Proceeding; Says A Final Outcome Is Expected In About 18-24 Months From Now

Financial news for ALXN dated on 2019-08-30: '\$AMGN lawyers, like the Yankees, don't go on losing streaks. \$ALXN now faces IPR challenge over Soliris patents -- an unexpected development, at least by many on the sell-side. Of course, this will take a long time to play out.' -STAT's Adam Feuerstein

Financial news for ALXN dated on 2019-08-30: Amgen Challenging Alexion Patents For SOLIRIS

Financial news for ALXN dated on 2019-08-30: 18 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ALXN dated on 2019-08-27: European Commission Approves Alexion's SOLIRIS For Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Financial news for ALXN dated on 2019-08-26: Alexion Trades Lower Amid Amgen-Celgene News

Financial news for ALXN dated on 2019-08-26: Alexion Pharmaceuticals Option Alert: Sep 20 \$110 Calls Sweep (3) near the Bid: 500 @ \$7.5 vs 822 OI; Earnings 10/23 Before Open [est] Ref=\$112.7

Financial news for ALXN dated on 2019-08-26: Alexion shares are trading lower potentially due to Amgen's acquisition of OTEZLA for \$13.4B. Last week rumors circulated that Amgen may be interested in acquiring Alexion.

Financial news for ALXN dated on 2019-08-26: 16 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ALXN dated on 2019-08-23: Shares of several healthcare companies are trading lower on escalated trade tensions after China announced it plans to impose a 5% to 10% tariff rate on \$75 billion worth of U.S. goods. Trump announced he will respond to China's tariffs this afternoon.

Financial news for ALXN dated on 2019-08-22: Alexion Pharmaceuticals shares are trading higher on reports that the company and Amgen could be nearing a deal.

Financial news for ALXN dated on 2019-08-22: '\$AMGN and \$ALXN are engaged in a rather protracted and nasty legal fight over biosimilar Soliris in Europe. Hard to reconcile this fact with the rumor of merger negotiations, right?' -STAT's Adam Feuerstein

Financial news for ALXN dated on 2019-08-21: Alexion Pharmaceuticals Option Alert: Jan 17 \$120 Calls Sweep (2) near the Ask: 991 @ \$9.65 vs 138 OI; Ref=\$114.65

Financial news for ALXN dated on 2019-08-21: Alexion Pharmaceuticals Option Alert: Nov 15 \$125 Calls Sweep (2) above Ask!: 800 @ \$5.451 vs 249 OI; Ref=\$114.34

Financial news for ALXN dated on 2019-08-13: Shares of several healthcare companies

are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for ALXN dated on 2019-07-31: Benzinga's Top Upgrades, Downgrades For July 31, 2019

Financial news for ALXN dated on 2019-07-31: JP Morgan Initiates Coverage On Alexion Pharmaceuticals with Overweight Rating

Financial news for ALXN dated on 2019-07-26: Alexion Reports Positive CHMP Opinion For SOLIRIS For Treatment Of NMOSD

Financial news for ALXN dated on 2019-07-25: Alexion Shares Spike Over \$120 Level On Volume As Traders Circulate Questionable Takeover Chatter From Unreliable Source

Financial news for ALXN dated on 2019-07-25: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$168

Financial news for ALXN dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for ALXN dated on 2019-07-24: Alexion Raises FY19 Guidance: Adj. EPS From \$9.25-\$9.45 To \$9.65-\$9.85 vs \$9.44 Estimate, Sales From \$4.675B-\$4.75B To \$4.75B-\$4.8B vs \$4.78B Est.

Financial news for ALXN dated on 2019-07-24: Alexion Pharmaceuticals Q2 Adj. EPS \$2.64 Beats \$2.33 Estimate, Sales \$1.203B Beat \$1.17B Estimate

Financial news for ALXN dated on 2019-07-24: Earnings Scheduled For July 24, 2019

Financial news for ALXN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for ALXN dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for ALXN dated on 2019-07-05: A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report

Financial news for ALXN dated on 2019-07-05: 5 Stocks To Watch For July 5, 2019

Financial news for ALXN dated on 2019-07-03: Alexion Pharma Reports ULTOMIRIS Received Marketing Authorization From EC For Adults With Paroxysmal Nocturnal Hemoglobinuria

Financial news for ALXN dated on 2019-06-28: Alexion Pharmaceuticals shares are trading higher after the company received FDA approval of SOLIRIS.

Financial news for ALXN dated on 2019-06-27: Alexion Confirms FDA Approval For Soliris

Financial news for ALXN dated on 2019-06-27: Alexion Pharmaceuticals PR Confirms FDA Approval For SOLIRIS

Financial news for ALXN dated on 2019-06-27: FDA Says Granted Approval Of Soliris To Alexion Pharmaceuticals

Financial news for ALXN dated on 2019-06-23: The 5 Most Expensive Drugs In US: What You Should Know

Financial news for ALXN dated on 2019-06-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for ALXN dated on 2019-06-20: Alexion Pharmaceuticals shares are trading higher after the FDA accepted for priority review the company's supplemental Biologics license application for ULTOMIRIS for the treatment of Atypical Hemolytic Uremic Syndrome.

Financial news for ALXN dated on 2019-06-20: FDA Accepts Supplemental Biologics License Application For Alexion's ULTOMIRIS Under Priority Review For Treatment Of Atypical Hemolytic Uremic Syndrome; FDA Sets Target ACTION Date Of Oct. 19

Financial news for ALXN dated on 2019-06-18: Alexion Pharma Reports ULTOMIRIS Received Marketing Authorization From Japan's Ministry Of Health, Labour And Welfare



For Treatment Of Adults With Paroxysmal Nocturnal Hemoglobinuria

Financial news for ALXN dated on 2019-06-14: Alexion Pharma Says 'Positive' Phase 3 Data for ULTOMIRIS Was Presented at the European Hematology Association Congress

Financial news for ALXN dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for ALXN dated on 2019-05-23: Citigroup Maintains Buy on Alexion Pharmaceuticals, Inc. - Common Stock, Lowers Price Target to \$165

Financial news for ALXN dated on 2019-05-23: Goldman Sachs Assumes Alexion Pharmaceuticals, Inc. - Common Stock at Neutral, Announces Price Target \$142

Financial news for ALXN dated on 2019-05-23: Wedbush Initiates Coverage On Alexion Pharmaceuticals, Inc. - Common Stock with Outperform Rating, Announces \$173 Price Target

Financial news for ALXN dated on 2019-05-16: Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.

Financial news for ALXN dated on 2019-05-14: Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.

Financial news for ALXN dated on 2019-05-03: Alexion Pharma Highlights New England Journal of Medicine Published Phase 3 PREVENT Data for SOLIRIS(r) in Patients with Neuromyelitis Optica Spectrum Disorder

Financial news for ALXN dated on 2019-04-26: Alexion Press Release Confirms Positive CHMP Opinion For ULTOMIRIS

Financial news for ALXN dated on 2019-04-26: Alexion Shares Unaffected As Traders Circulate EMA Positive Opinion For Co.'s Ultomiris

Financial news for ALXN dated on 2019-04-26: Raymond James Maintains Outperform on Alexion Pharmaceuticals, Inc. - Common Stock, Raises Price Target to \$164

Financial news for ALXN dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for ALXN dated on 2019-04-25: Alexion Pharmaceuticals, Inc Raises FY19 Adj. EPS Guidance From \$9.10-\$9.30 To \$9.25-\$9.45 vs \$9.31 Est., Raises Sales Guidance From \$4.625B-\$4.70B To \$4.625B-\$4.75B vs \$4.75B Est.

Financial news for ALXN dated on 2019-04-25: Alexion Pharmaceuticals Q1 Adj. EPS \$2.39 Beats \$2.18 Estimate, Sales \$1.14B Beat \$1.13B Estimate

Financial news for ALXN dated on 2019-04-25: Earnings Scheduled For April 25, 2019

Financial news for ALXN dated on 2019-04-21: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for ALXN dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for ALXN dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for ALXN dated on 2019-04-10: Raymond James Earlier Reinstated Outperform on Alexion Pharmaceuticals, Announced \$161 Price Target

Financial news for ALXN dated on 2019-04-04: 'Three drug makers settle allegations of using charities to pay kickbacks to Medicare patients' -Stat News

Financial news for ALXN dated on 2019-03-20: Alexion And Zealand Pharma Announce Collaboration To Discover And Develop Peptide Therapies For Complement-Mediated Diseases; Zealand To Receive \$25M Upfront And \$15M Equity Investment

Financial news for ALXN dated on 2019-03-20: Alexion And Affibody Announce Partnership To Co-Develop Anti-FcRn Affibody Molecule

Financial news for ALXN dated on 2019-03-08: Alexion Highlights Publication Of Interim Data From Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy, Safety Of SOLIRIS for Generalized Myasthenia Gravis In Muscle & Nerve

Financial news for ALXN dated on 2019-02-22: FDA Grants Priority Review And Accepts Alexion Pharmaceuticals's sBLA Of SOLIRIS As A Treatment For Patients With Neuromyelitis Optica Spectrum Disorder

Financial news for ALXN dated on 2019-02-22: Guggenheim Initiates Coverage On Alexion Pharmaceuticals with Neutral Rating, Announces \$135 Price Target

Financial news for ALXN dated on 2019-02-12: 8 Biggest Price Target Changes For Tuesday

Financial news for ALXN dated on 2019-02-12: Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to \$175

Financial news for ALXN dated on 2019-02-04: Alexion Pharma shares are trading lower on weak 2019 sales guidance despite reporting better than expected Q4 EPS and revenue.

Financial news for ALXN dated on 2019-02-04: Alexion Pharma shares are trading higher after the company reported better than expected Q4 EPS and revenue results. Alexion also announced better than expected 2019 EPS guidance.

Financial news for ALXN dated on 2019-02-04: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ALXN dated on 2019-02-04: A Peek Into The Markets: US Stock Futures Edge Higher, Alphabet Earnings In Focus

Financial news for ALXN dated on 2019-02-04: Alexion Pharmaceuticals Sees FY2019 EPS \$9.10-9.30 vs \$8.73 Est; Sees Sales \$4.63B-4.70B vs \$4.75B Est

Financial news for ALXN dated on 2019-02-04: Alexion Pharmaceuticals Q4 EPS \$2.14 Beats \$1.82 Estimate, Sales \$1.129B Beat \$1.06B Estimate

Financial news for ALXN dated on 2019-02-04: 8 Stocks To Watch For February 4, 2019

Financial news for ALXN dated on 2019-02-04: Earnings Scheduled For February 4, 2019

Financial news for ALXN dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for ALXN dated on 2019-01-31: Fortress Biotech shares are trading higher after the company highlighted a collaboration between Caelum Biosciences, founded by Fortress, and Alexion Pharmaceuticals to develop a light chain amyloidosis therapy.

Financial news for ALXN dated on 2019-01-31: BZ NOTE: Fortress Biotech Founded Caelum Biosciences, Owns ~40%

Financial news for ALXN dated on 2019-01-31: Fortress Biotech Highlights Strategic Partnership With Alexion, Caelum Biosciences For CAEL-101

Financial news for ALXN dated on 2019-01-31: UPDATE: Alexion Will Have Option To Acquire Caelum Based On Phase 2 Data

Financial news for ALXN dated on 2019-01-31: UPDATE: Alexion Says Caelum Biosciences Will Receive Up To \$60M For Equity Investment, Option Fee

Financial news for ALXN dated on 2019-01-31: Alexion Reports Collaboration With Caelum Biosciences To Develop Target Therapy For Light Chain Amyloidosis

Financial news for ALXN dated on 2019-01-28: A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus

Financial news for ALXN dated on 2019-01-28: Alexion Announces 'Positive' Top-Line Results from Phase 3 Study of ULTOMIRIS in Complement Inhibitor-Naive Patients with atypical Hemolytic Uremic Syndrome

Financial news for ALXN dated on 2018-12-21: Alexion Pharmaceuticals In 8-K Says Has Established A Whole Acquisition Cost For ULTOMIRIS In US Of \$6,404 Per Vial

Financial news for ALXN dated on 2018-12-21: Alexion Press Release Confirms Co. Has Received Early FDA Approval For ULTOMIRIS In Adults With Paroxysmal Nocturnal Hemoglobinuria; NOTE: This Was Earlier Disclosed On The FDA's Site

Financial news for ALXN dated on 2018-12-21: Hearing Alexion Pharmaceuticals Received

FDA Approval For ULTOMIRIS

Financial news for ALXN dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for ALXN dated on 2018-12-10: 5 Biotech Companies To Keep On Your M&A Watchlist For 2019

Financial news for ALXN dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for ALXN dated on 2018-11-16: UPDATE: Alexion Says Believes Has Valid Legal Defense Against Chugai's Infringement Claims; Co. Says Intends To Oppose Claims, Will Proceed With Business Plans For ALXN1210

Financial news for ALXN dated on 2018-11-16: Alexion Pharma 8-K Shows Chugai Pharma Filed Complaint Against Co. Alleging 'ALXN1210 infringes a U.S. patent held by Chugai'

Financial news for ALXN dated on 2018-11-14: From 13-F Filing: Temasek Cuts Share Stake in Alibaba, JD.com, Alexion

Financial news for ALXN dated on 2018-10-25: Citigroup Maintains Buy on Alexion Pharmaceuticals, Lowers Price Target to \$190

Financial news for ALXN dated on 2018-10-24: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ALXN dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for ALXN dated on 2018-10-24: Alexion Raises FY18 Guidance: Adj. EPS From \$7-\$7.15 To \$7.45-\$7.60 vs \$7.24 Estimate, Sales From \$3.98B-\$4.01B To \$4.02B-\$4.05B vs \$4.04B Est.

Financial news for ALXN dated on 2018-10-24: Alexion Pharmaceuticals, Inc. Q3 EPS \$2.02 Beats \$1.74 Estimate, Sales \$1.027B Beat \$1.02B Estimate

Financial news for ALXN dated on 2018-10-24: UPDATE: Dicerna To Receive \$22M Upfront Payment, \$15M Equity Investment And Potential For Added Milestone-Dependent, Royalty Payments

Financial news for ALXN dated on 2018-10-24: Alexion, Dicerna Report Collaboration To Discover, Develop RNAi Therapies For Complement-Mediated Diseases

Financial news for ALXN dated on 2018-10-24: Earnings Scheduled For October 24, 2018

Financial news for ALXN dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for ALXN dated on 2018-10-11: Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to \$165

Financial news for ALXN dated on 2018-09-26: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ALXN dated on 2018-09-26: Alexion Pharmaceuticals shares are up 4.6% after the company earlier announced it will acquire Syntimmune for \$400 million up front and up to \$800 million in potential milestones; Total contract value is up to \$1.2 billion.

Financial news for ALXN dated on 2018-09-26: Alexion To Acquire Syntimmune; Alexion Will Acquire Syntimmune For An Upfront Payment Of \$400M With The Potential For Milestone-Dependent Payments Of Up To \$800, For Total Value Of \$1.2B

Financial news for ALXN dated on 2018-09-25: 10 Biggest Price Target Changes For Tuesday

Financial news for ALXN dated on 2018-09-25: Citigroup Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to \$195

Financial news for ALXN dated on 2018-09-25: Stifel Nicolaus Maintains Hold on Alexion Pharmaceuticals, Raises Price Target to \$136

Financial news for ALXN dated on 2018-09-25: 51 Biggest Movers From Yesterday

Financial news for ALXN dated on 2018-09-24: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for ALXN dated on 2018-09-24: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for ALXN dated on 2018-09-24: Alexion Pharma's Phase 3 Study of Soliris Met its Primary Endpoint

Financial news for ALXN dated on 2018-08-29: Watching Shares of Alexion, Seeing Some Social Media Mention The Company's Brazil Offices Were Visited By Govt. In a Tax Audit, Unconfirmed

Financial news for ALXN dated on 2018-08-20: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for ALXN dated on 2018-08-20: Alexion Pharma Granted Priority Review by the FDA for its Biologics License Application for ALXN1210

Financial news for ALXN dated on 2018-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2018

Financial news for ALXN dated on 2018-08-07: Stifel Nicolaus Downgrades Alexion Pharmaceuticals to Hold, Lowers Price Target to \$130

Financial news for ALXN dated on 2018-07-27: Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to \$157

Financial news for ALXN dated on 2018-07-27: JP Morgan Maintains Overweight on Alexion Pharmaceuticals, Raises Price Target to \$188

Financial news for ALXN dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for ALXN dated on 2018-07-26: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALXN dated on 2018-07-26: UPDATE: Alexion Raises FY18 Adj. EPS Outlook From \$6.75-\$6.90 To \$7-\$7.15 vs \$7.03 Estimate, Total Sales From \$3.925B-\$3.985B To \$3.98B-\$4.01B vs \$3.95B Est.

Financial news for ALXN dated on 2018-07-26: Alexion Raises FY18 Guidance

Financial news for ALXN dated on 2018-07-26: Alexion Pharmaceuticals Q2 EPS \$2.07 Beats \$1.70 Estimate, Sales \$1.045B Beat \$977.89M Estimate

Financial news for ALXN dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ALXN dated on 2018-06-28: Alexion Pharma Submits ALXN1210 For Approval in the EU, Japanese Submission Expected in 2H 2018

Financial news for ALXN dated on 2018-06-19: UPDATE: Alexion Says Submission For Priority Review, Approval In EU On Track For Mid Year, In Japan For 2H'18

Financial news for ALXN dated on 2018-06-19: Alexion Pharma Reports Submission Of Application For Priority Review, Approval Of ALXN1210 As Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria In US

Financial news for ALXN dated on 2018-06-11: Alexion Snd Complement Pharma Announce Partnership To Co-Develop Pre-Clinical Complement Inhibitor For Neurodegenerative Disorders; Alexion Has Option To Acquire Complement During Term Of Agree

Financial news for ALXN dated on 2018-06-05: Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$154

Financial news for ALXN dated on 2018-05-31: '\$OMER says OMS721 deserves rapid approval for a deadly complication of bone marrow transplants b/c there are no approved treatments. But that's not true. An expert tells me \$ALXN Soliris works very well'

Financial news for ALXN dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for ALXN dated on 2018-05-25: Alexion Pharma Reports Offer For Wilson Therapeutics Has Been Accepted

Financial news for ALXN dated on 2018-05-25: Alexion Announces Offer for Wilson Therapeutics Accepted

Financial news for ALXN dated on 2018-05-08: Alexion Pharma Shares Down ~\$1.15 Over Last Few Mins. As Traders Circulate Jefferies Comments European Patent Office's

Examining Division Issued Rejection Of Co.'s New Patent For Soliris

Financial news for ALXN dated on 2018-05-06: Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More

Financial news for ALXN dated on 2018-04-30: Citigroup Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to \$173.00

Financial news for ALXN dated on 2018-04-27: Stifel Nicolaus Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to \$155.00

Financial news for ALXN dated on 2018-04-27: 50 Biggest Movers From Yesterday

Financial news for ALXN dated on 2018-04-26: Alexion Shares Up 11.4% After Co. Earlier Reported Q1 Beat And Raised FY18 Outlook

Financial news for ALXN dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for ALXN dated on 2018-04-26: 'Congrats to \$ALXN for delivering the first, strong biotech earnings report in Q1 -- with added bonus of positive '1210 switch study. Will anyone care?'-STAT's Adam Feuerstein Tweets

Financial news for ALXN dated on 2018-04-26: UPDATE: Alexion Pharma Raises FY18 Adj. EPS Outlook From \$6.60-\$6.80 To \$6.75-\$6.90 vs \$6.86 Est., Sales From \$3.85B-\$3.95B To \$3.925B-\$3.985B vs \$3.98B Est.

Financial news for ALXN dated on 2018-04-26: Alexion Pharma Raises Guidance

Financial news for ALXN dated on 2018-04-26: Alexion Pharma Q1 Adj. EPS \$1.68 Beats \$1.50 Est., Sales \$930.9M Beats \$923M Est.

Financial news for ALXN dated on 2018-04-20: Alexion Issues Statement On Superior Court Justice Decision in Brazil Regarding Soliris, Says No Compulsory License of Soliris Was Requested or Granted in Brazil, Co. Is Evaluating The Full Decision Before Exploring Options to Respond

Financial news for ALXN dated on 2018-04-20: UPDATE: Alexion Offers Clarification No Compulsory License Of Soliris Was Required Or Granted In Brazil

Financial news for ALXN dated on 2018-04-20: UPDATE: Alexion Says 'Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris'

Financial news for ALXN dated on 2018-04-20: Alexion Issues Statement On STJ Decision In Brazil Involving Soliris

Financial news for ALXN dated on 2018-04-20: UPDATE: Leerink On Alexion Warns Of Near-Term Negative Impact On Stock But Says Given Regulatory Decision, Biosimilar Developer Of Eculizumab Would Not Be Able To Manufacture, Sell An Alternative Product In Brazil For At Least 2-3 Years

Financial news for ALXN dated on 2018-04-20: Hearing Leerink Defending Alexion

Financial news for ALXN dated on 2018-04-20: The Federal AG Office Of Brazil Says It Won A Unanimous Decision In The Third Panel Of The Superior Court Of Justice That Makes Public The Soliris Patent

Financial news for ALXN dated on 2018-04-20: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for ALXN dated on 2018-04-20: Hearing Brazil Breaks Patent Of Alexion's Soliris

Financial news for ALXN dated on 2018-04-20: Alexion Shares Spike Sharply Below \$110 Level, Down ~3% Over Last Min.

Financial news for ALXN dated on 2018-04-17: Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'

Financial news for ALXN dated on 2018-04-11: Alexion to Acquire Wilson Therapeutics for ~\$855M in Cash

Financial news for ALXN dated on 2018-03-19: Nomura Maintains Buy on Alexion Pharmaceuticals, Raises Price Target to \$156.00

Financial news for ALXN dated on 2018-03-16: Credit Suisse Maintains Outperform on Alexion Pharmaceuticals, Raises Price Target to \$149.00

Financial news for ALXN dated on 2018-03-15: Alexion Says Safety Profile of ALXN1210 Consistent with That Seen for Soliris, Regulatory Submissions Planned in the United States, European Union, and Japan in the Second Half of 2018; Conf. Call Scheduled For 8:30 a.m. Today

Financial news for ALXN dated on 2018-03-15: Alexion's Phase 3 Study Of ALXN1210 Met Co-Primary Endpoints And All Four Secondary Endpoints

Financial news for ALXN dated on 2018-02-14: 13F From Loeb's Third Point Shows Liquidated Position In Alexion

Financial news for ALXN dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for ALXN dated on 2018-02-09: BMO Capital Maintains Outperform on Alexion Pharmaceuticals, Raises price target to \$180.00

Financial news for ALXN dated on 2018-02-09: Morgan Stanley Maintains Overweight on Alexion Pharmaceuticals, Raises price target to \$151.00

Financial news for ALXN dated on 2018-02-09: Leerink Swann Maintains Outperform on Alexion Pharmaceuticals, Lowers price target to \$153.00

Financial news for ALXN dated on 2018-02-09: Deutsche Bank Maintains Buy on Alexion Pharmaceuticals, Lowers price target to \$161.00

Financial news for ALXN dated on 2018-02-09: Citigroup Maintains Buy on Alexion Pharmaceuticals, Lowers price target to \$170.00

Financial news for ALXN dated on 2018-02-08: Alexion Sees FY18 Adj. EPS \$6.60 to \$6.80 vs \$7.01 Est., Sales \$3.85B to \$3.95B vs \$4.07B Est.

Financial news for ALXN dated on 2018-02-08: Alexion Reports Adj. EPS \$1.48 vs \$1.28 Est., Sales \$909.7M vs \$880.7M Est.

Financial news for ALXN dated on 2018-01-29: AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Financial news for ALXN dated on 2018-01-18: The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse

Financial news for ALXN dated on 2018-01-18: Credit Suisse Assumes Alexion Pharmaceuticals at Outperform, Announces price target \$147.00

Financial news for ALXN dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for ALXN dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for ALXN dated on 2018-01-04: Benzinga's Top Upgrades, Downgrades For January 4, 2018

Financial news for ALXN dated on 2018-01-04: Raymond James Downgrades Alexion Pharmaceuticals to Outperform

Financial news for ALXN dated on 2018-01-04: Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam

Financial news for ALXN dated on 2018-01-03: Alexion, Comcast, Paypal, Visa: 'Fast Money Halftime Report' Traders Share Their Picks

Financial news for ALXN dated on 2018-01-02: Alexion And Elliott Management Agree To Work Together On Identifying A New Board Member

Financial news for ALXN dated on 2017-12-26: Alexion's Soliris Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis

Financial news for ALXN dated on 2017-12-20: Oppenheimer Stays Bullish On Alexion Pharma

Financial news for ALXN dated on 2017-12-19: Oppenheimer Serves Up 29 Top Stock Ideas For January

Financial news for ALXN dated on 2017-12-18: Benzinga's Top Upgrades, Downgrades For December 18, 2017

Financial news for ALXN dated on 2017-12-18: Baird Upgrades Alexion Pharmaceuticals to Outperform

Financial news for ALXN dated on 2017-12-11: Alexion Reports Phase 1b/2 Results For ALXN1210 Show 'Rapid And Sustained Reduction Of Plasma Lactate Dehydrogenase Levels' At 8 Months, Well Tolerated, Successful Transition Of Patients To Phase 3 Dosing Regimen

Financial news for ALXN dated on 2017-12-08: Alexion Therapeutics Shares Up 8.6% Premarket Fri. Following Late Thurs. NY Times Report 'Elliott Management Is Said Push for Changes at Alexion'

Financial news for ALXN dated on 2017-12-08: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for ALXN dated on 2017-12-07: Alexion and Halozyme Enter License Agreement for ENHANZE, Halozyme to Receive a \$40M Upfront Payment

Financial news for ALXN dated on 2017-11-30: Oppenheimer's Top Stock Picks For December

Financial news for ALXN dated on 2017-11-07: Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead

Financial news for ALXN dated on 2017-11-06: Alexion Reports Received New Japanese Patent For Soliris

Financial news for ALXN dated on 2017-10-26: Alexion Narrows FY17 Sales Outlook From \$3.45B-\$3.525B To \$3.475B-\$3.525B vs \$3.52B Est.

Financial news for ALXN dated on 2017-10-26: Alexion Raises FY17 Adj. EPS Outlook From \$5.40-\$5.55 To \$5.50-\$5.65 vs \$5.60 Est.

Financial news for ALXN dated on 2017-10-26: Alexion Pharma Reports Q3 Adj. EPS \$1.44 vs \$1.32 Est., Sales \$859M vs \$864.5M Est.

Financial news for ALXN dated on 2017-10-26: Earnings Scheduled For October 26, 2017

Financial news for ALXN dated on 2017-10-24: Is A Beat In Store For Alexion This Earnings Season?

Financial news for ALXN dated on 2017-10-24: What To Make Of Alexion's New FDA Approval

Financial news for ALXN dated on 2017-10-24: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALXN dated on 2017-10-23: Alexion Announces FDA Approves Soliris for Treatment of Patients with Generalized Myasthenia Gravis

Financial news for ALXN dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for ALXN dated on 2017-10-23: REMINDER: Alexion Pharmaceuticals Has PDUFA Date For Eculizumab sBLA Today

Financial news for ALXN dated on 2017-10-23: PiperJaffray Assumes Alexion Pharmaceuticals at Overweight, Announces price target \$170.00

Financial news for ALXN dated on 2017-10-16: 29 Top Stock Ideas For October And Beyond

Financial news for ALXN dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for ALXN dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for ALXN dated on 2017-09-13: Alexion Announces Positive Interim Analysis from Phase 3 Open-Label Extension Study of Soliris Treatment for Patients with Refractory Generalized Myasthenia Gravis

Financial news for ALXN dated on 2017-09-12: Watching Alexion Shares Bouncing Off Session Lows As Traders Circulating Sale Speculation

Financial news for ALXN dated on 2017-09-12: Alexion Will Move HQ To Boston, Massachusetts By Mid '18

Financial news for ALXN dated on 2017-09-12: Alexion Pharma Reaffirms FY17 Sales Outlook

Financial news for ALXN dated on 2017-09-12: Alexion Pharma Announces Restructuring, 20% Workforce Cut Back, Sees \$250M of Non-GAAP Pre-tax Savings by 2019

Financial news for ALXN dated on 2017-09-11: Your Easy Guide To Credit Suisse's New Top Stocks List

Financial news for ALXN dated on 2017-09-05: Alexion Pharma Stock A Buy After A Pair Of 'De-Risking' Events In 2017

Financial news for ALXN dated on 2017-09-05: Benzinga's Top Upgrades, Downgrades For September 5, 2017

Financial news for ALXN dated on 2017-09-05: JP Morgan Upgrades Alexion Pharmaceuticals to Overweight

Financial news for ALXN dated on 2017-09-01: Sell In May And Go Away? Doing So With These Stocks Was A Mistake

Financial news for ALXN dated on 2017-08-17: Benzinga's Top Upgrades, Downgrades For August 17, 2017

Financial news for ALXN dated on 2017-08-17: Evercore ISI Group Initiates Coverage On Alexion Pharmaceuticals with In-Line Rating, Announces \$137.00 Price Target

Financial news for ALXN dated on 2017-08-15: Alexion Pharma Reports 3 New US Patents For Soliris, Extending Patent Protection Into 2027

Financial news for ALXN dated on 2017-08-11: 13F From Loeb's Third Point Shows New 1.25M Share Stake In Alexion Pharma

Financial news for ALXN dated on 2017-08-10: Alexion Pharma Reports Strategic Partnership With Sema4 For Rare Disease Diagnostics, Systems Biology

Financial news for ALXN dated on 2017-08-04: Alexion Shares Move Lower As Traders Circulating clinicaltrials.gov Alert Participant Recruitment For Study Of Samalizumab In Patients With Advanced Cancer Has Been Suspended

Financial news for ALXN dated on 2017-08-01: 3 ETFs To Watch Out For On Biotech Earnings

Financial news for ALXN dated on 2017-07-28: Oppenheimer Upgrades Alexion Pharmaceuticals to Outperform

Financial news for ALXN dated on 2017-07-27: 18 Biggest Mid-Day Gainers For Thursday

Financial news for ALXN dated on 2017-07-27: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALXN dated on 2017-07-27: UPDATE: Alexion Raises FY17 Sales Outlook From \$3.4B-\$3.5B To \$3.45B-\$3.525B vs \$3.47B Est., Adj. EPS From \$5.10-\$5.30 To \$5.40-\$5.55 vs \$5.33 Est.

Financial news for ALXN dated on 2017-07-27: Alexion Reports Q2 Adj. EPS \$1.56 vs \$1.26 Est., Sales \$912M vs \$845.5M Est.; Raises Outlook

Financial news for ALXN dated on 2017-07-07: The Market In 5 Minutes

Financial news for ALXN dated on 2017-07-06: Exclusive: Alexion Responds To Government Probe

Financial news for ALXN dated on 2017-07-06: UPDATE: Alexion Tells Benzinga 'We are cooperating with this inquiry and are responding to the subpoena,' Referring To Previously Disclosed Request For Documents Related To Provision Of Drugs To Medicare Patients

Financial news for ALXN dated on 2017-07-06: Alexion Responds To Reports Of HHS Probe, Tells Benzinga: 'We are aware' HHS Working With DoJ Related to Previously Disclosed Inquiry; 'Alexion has not received a request for records from the HHS Office of Inspector General pertaining to any other matter'

Financial news for ALXN dated on 2017-07-06: Alexion Shares Falling, Company Reportedly Under Investigation By HHS Inspector General



Financial news for ALXN dated on 2017-07-05: Alexion Announces Funding Agreement with NICE, NHS England for Strensiq for Patients with Pediatric-onset Hypophosphatasia

Financial news for ALXN dated on 2017-06-23: Alexion Receives Positive CHMP Opinion for Soliris In The EU

Financial news for ALXN dated on 2017-06-23: Alexion Reports Positive CHMP Opinion For Soliris For Treatment Of Patients With Refractory Generalized Myasthenia Gravis In EU

Financial news for ALXN dated on 2017-06-15: C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen

Financial news for ALXN dated on 2017-06-14: Alexion's New CFO Continues To Shore Up Investor Concerns

Financial news for ALXN dated on 2017-06-14: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for ALXN dated on 2017-06-14: Alexion Pharmaceuticals Spikes to High of \$117.98 After Co Announced Paul Clancy as New CFO on Tuesday

Financial news for ALXN dated on 2017-06-14: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ALXN dated on 2017-06-14: A Peek Into The Markets: U.S. Stock Futures Edge Higher; All Eyes On Fed Decision

Financial news for ALXN dated on 2017-06-14: Alexion Pharmaceuticals +\$5.00 Premarket @ \$113.00; Co Announced Paul Clancy as New CFO on Tuesday

Financial news for ALXN dated on 2017-06-13: Alexion Names Paul Clancy CFO

Financial news for ALXN dated on 2017-06-07: UPDATE: Alexion Shares Spiked as Much as 2.8% But Gains Have Since Been Pared; Shares Now Up Only 0.5% For Session

Financial news for ALXN dated on 2017-06-07: Alexion Pharma Shares Recently Spike Into Positive Territory, Now Up ~0.5%; Traders Circulating Word Of New Soliris Patent

Financial news for ALXN dated on 2017-06-07: Alexion Pharma Spikes to High of \$103.49 on Volume

Financial news for ALXN dated on 2017-05-30: Analyst: With This Much Pessimism Priced In, Alexion Begins To Look Attractive

Financial news for ALXN dated on 2017-05-30: Adam Feuerstein Tweets: \$ALXN sentiment is at all-time low, which is a buying opportunity, says @sharkbiotech. He explains why he's buying >

Financial news for ALXN dated on 2017-05-26: Alexion Shares Dip ~\$1.25 Over Last Min as \$99 Support Level Breaks; Stock Down 0.7% for Session

Financial news for ALXN dated on 2017-05-25: 2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals

Financial news for ALXN dated on 2017-05-25: Benzinga's Top Upgrades, Downgrades For May 25, 2017

Financial news for ALXN dated on 2017-05-25: The Market In 5 Minutes

Financial news for ALXN dated on 2017-05-25: Morgan Stanley Upgrades Alexion Pharmaceuticals to Overweight

Financial news for ALXN dated on 2017-05-24: Benzinga's Option Alert Recap From May 24

Financial news for ALXN dated on 2017-05-24: Option Alert: Alexion Aug 105 Calls: 1500 @ ASK \$6.60: 1528 traded vs 84 OI: Earnings 7/27 Before Open (est) \$99.97 Ref

Financial news for ALXN dated on 2017-05-24: The Market In 5 Minutes

Financial news for ALXN dated on 2017-05-23: Mid-Afternoon Market Update: America's Car-Mart Rises On Earnings Beat; Alexion Shares Drop

Financial news for ALXN dated on 2017-05-23: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ALXN dated on 2017-05-23: Hearing Raymond James Out Defending Alexion

Financial news for ALXN dated on 2017-05-23: Mid-Day Market Update: Kirkland's Drops After Weak Q1 Results; Helios and Matheson Analytics Shares Surge

Financial news for ALXN dated on 2017-05-23: Alexion Shares Rebound Off Session Lows; Hearing Cowen Has Said Stock Price Downside Amid CFO Departure is Overdone

Financial news for ALXN dated on 2017-05-23: Alexion Shares Dip to Session Lows, Now Down 10% as Hearing JP Morgan Downgraded Stock from Overweight to Neutral

Financial news for ALXN dated on 2017-05-23: Alexion Announces CFO Dave Anderson to Resign

Financial news for ALXN dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for ALXN dated on 2017-05-15: Alexion Pharmaceuticals Says Patients Experienced Sustained Improvements In Physical Function, Speed, Agility And Strength Following Treatment Of Strensiq

Financial news for ALXN dated on 2017-05-09: Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip

Financial news for ALXN dated on 2017-05-08: Hearing Raymond James Says Would Be Buyers of Alexion, Maintains Strong Buy Rating

Financial news for ALXN dated on 2017-05-08: Martin Shkreli in Facebook Post Says He Likes Horizon Pharma For A Pop, But 'Wouldn't Marry It'; Likes Alexion A Lot On The Pullback

Financial news for ALXN dated on 2017-05-08: Hearing Alexion Has Said Brazilian Authorities Were at Office Related to Police Announcement of Probe Into Fraudulent Sales of Soliris

Financial news for ALXN dated on 2017-05-08: Hearing Alexion Defended At Barclays, Firm Saying Brazilian Headline Looks Onerous But Don't See Major Fundamental Concern Given Good U.S. Soliris Growth, Would Be Buyers On Weakness

Financial news for ALXN dated on 2017-05-08: UPDATE: Alexion In Statement Says Co. Aware Authorities Were At Company's Office In Brazil, 'They have since left and we are fully cooperating with authorities'

Financial news for ALXN dated on 2017-05-08: Alexion Spokesperson Confirms Brazil Offices Have Been Raided By Brazilian Authorities

Financial news for ALXN dated on 2017-04-27: UPDATE: Alexion Pharma Raises FY17 Adj. EPS Outlook to \$5.10-\$5.30 vs \$5.23 Est., Affirms Sales Outlook for \$3.4B-\$3.5B vs \$3.48B Est.

Financial news for ALXN dated on 2017-04-27: Alexion Raises FY17 Adj. EPS Outlook

Financial news for ALXN dated on 2017-04-27: Alexion Pharma Reports Q1 Adj. EPS \$1.38 vs \$1.23 Est., Sales \$870M vs \$827M Est.

Financial news for ALXN dated on 2017-04-25: Watch These 8 Huge Call Purchases In Tuesday Trade

Financial news for ALXN dated on 2017-04-24: Benzinga's Option Alert Recap From April 24

Financial news for ALXN dated on 2017-04-24: Option Alert: Alexion Apr 28th 122 Calls Sweep: 518 @ ASK \$2.75: 519 traded vs 14 OI: Earnings 4/27 Before Open \$119.01 Ref

Financial news for ALXN dated on 2017-04-24: UPDATE: FT Article Says Investor Argued That Sanofi Should Focus Efforts On Smaller Acquisitions Or Target A Co. That's Unlikely To Draw Rival Bidders Such As Alexion

Financial news for ALXN dated on 2017-04-24: Hearing FT Reporting Sanofi May Be In Talks With Alexion Pharma

Financial news for ALXN dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for ALXN dated on 2017-03-30: UBS Initiates Coverage On Alexion Pharmaceuticals With Buy

Financial news for ALXN dated on 2017-03-27: Alexion Announces Ludwig Hatson CEO

Financial news for ALXN dated on 2017-03-22: Alexion Submits Application in Japan for Soliris

Financial news for ALXN dated on 2017-03-20: Leerink Presents: Your 2017 Biopharma Catalyst Tracker

Financial news for ALXN dated on 2017-03-17: 15 Biggest Mid-Day Gainers For Friday

Financial news for ALXN dated on 2017-03-17: Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates

Financial news for ALXN dated on 2017-03-17: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for ALXN dated on 2017-03-16: UPDATE: Arbutus Says Alexion Will Pay \$7.5M Upfront, Up to \$75M for Achievement of Milestones

Financial news for ALXN dated on 2017-03-16: Arbutus Biopharma Shares Halted for News Pending: Reports Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

Financial news for ALXN dated on 2017-03-08: Jim Cramer Weighs In On Alexion Pharmaceuticals And Lowe's Companies

Financial news for ALXN dated on 2017-03-08: Alexion Pharma sBLA Filing of Soliris Accepted by the FDA

Financial news for ALXN dated on 2017-03-07: Raymond James Institutional Investors Conference Continues Today; Presenters Include Arrow Electronics, Insulet, JB Hunt, HCA Holdings, Palo Alto, Alexion, Moody's, Pier 1, & ACADIA Pharama

Financial news for ALXN dated on 2017-03-06: Cowen Annual Healthcare Conference Begins Today; Presenters Include Insulet, PARAXEL, Zoetis, Alexion, Bristol-Myers, Acadia, Alnylam, Axovant, Ardelyx, Aurinia Pharma, And Puma Biotech

Financial news for ALXN dated on 2017-03-02: Alexion Founder Leonard Bell To Retire As Chairman And Board Member Effective May 10

Financial news for ALXN dated on 2017-03-02: Benzinga's Top Upgrades, Downgrades For March 2, 2017

Financial news for ALXN dated on 2017-03-02: Nomura Initiates Coverage On Alexion Pharmaceuticals at Buy

Financial news for ALXN dated on 2017-02-23: Benzinga's Option Alert Recap From February 23

Financial news for ALXN dated on 2017-02-23: Option Alert: Alexon May 160 Calls Sweep: 813 @ ASK \$1.649: 813 traded vs 158 OI: Earnings 4/27 Before Open (est) \$128.97 Ref

Financial news for ALXN dated on 2017-02-19: Barron's Picks And Pans: General Motors, Hess, Biotechs And More

Financial news for ALXN dated on 2017-02-16: JPMorgan Raises Alexion Price Target From \$160 To \$170 And Reiterates Overweight Position

Financial news for ALXN dated on 2017-02-16: Alexion Says Company Will Not Add Patients To Ongoing SBC-103 Study Nor Start New Studies Until 'We Really Understand What's Happening' In The Trial

Financial news for ALXN dated on 2017-02-16: Alexion Sees FY 2017 EPS \$5.00 to \$5.25 vs \$5.54 Est, Revenue \$3.4B to \$3.5B vs \$3.5B Est

Financial news for ALXN dated on 2017-02-16: Alexion Increases Buyback to \$1B

Financial news for ALXN dated on 2017-02-16: Alexion Q4 EPS \$1.26 vs \$1.25 Est, Revenue \$831M vs \$837M Est

Financial news for ALXN dated on 2017-02-16: Earnings Scheduled For February 16, 2017

Financial news for ALXN dated on 2017-02-15: Alexion Pharma Shares Volatile Recently Amid Report Co.'s Kanuma Was Not Recommended by UK's Nice for LAL

Financial news for ALXN dated on 2017-02-07: Benzinga's Option Alert Recap From February 7

Financial news for ALXN dated on 2017-02-07: Option Alert: Alexion Feb 135 Calls:

2187 @ ASK \$1.35: 2230 traded vs 1536 OI: Earnings 2/16 Before Open \$126.59 Ref

Financial news for ALXN dated on 2017-01-11: Option Alert: Alexion Feb 140 Calls: 550 @ ASK \$6.60: 573 traded vs 382 OI: Earnings 2/16 Before Open \$136.60 Ref

Financial news for ALXN dated on 2017-01-09: Alexion Execs At JPM Healthcare Conf. Say Co Will Be Careful With M&A Cash Deployment

Financial news for ALXN dated on 2017-01-09: Alexion CEO At JPM Healthcare Conf. Says The Company Is Not For Sale

Financial news for ALXN dated on 2017-01-09: Alexion Submits U.S. and EU Applications Seeking Approval of Soliris (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis

Financial news for ALXN dated on 2017-01-09: The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know

Financial news for ALXN dated on 2017-01-06: Alexion Granted Orphan Drug Designation for for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Financial news for ALXN dated on 2017-01-05: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ALXN dated on 2017-01-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALXN dated on 2017-01-04: UPDATE: Alexion Says Audit And Finance Committee Concludes No Need To Restate Financials Due To Investigation

Financial news for ALXN dated on 2017-01-04: UPDATE: Alexion Affirms FY16 Outlook: Sales \$3.05B-\$3.1B vs \$3.09B, Adj. EPS \$4.50-\$4.65 vs \$4.64 Est.

Financial news for ALXN dated on 2017-01-04: Alexion Affirms FY16 Outlook

Financial news for ALXN dated on 2016-12-27: Here Are 7 Of The Biggest Market Catalysts Happening In January

Financial news for ALXN dated on 2016-12-22: Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis

Financial news for ALXN dated on 2016-12-22: Adam Feuerstein Tweets: \$ALXN -- Leerink's Porges pounding table on stock as THE big-cap buy for 2017. Recent turmoil turns out fine + likely activist entry.

Financial news for ALXN dated on 2016-12-21: Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab, Did Not Meet Primary Endpoint

Financial news for ALXN dated on 2016-12-20: Hearing Street Insider Reporting Alexion Pharmaceutical Said To Receive Takeover Approach

Financial news for ALXN dated on 2016-12-20: Alexion Shares Spiking Higher

Financial news for ALXN dated on 2016-12-15: Benzinga's Top Upgrades, Downgrades For December 15, 2016

Financial news for ALXN dated on 2016-12-15: Oppenheimer Initiates Coverage On Alexion Pharmaceuticals at Perform

Financial news for ALXN dated on 2016-12-14: Alexion Shares Up ~\$1 Over Last Min as Traders Passing Around Unconfirmed Chatter

Financial news for ALXN dated on 2016-12-13: 15 Biggest Mid-Day Losers For Tuesday

Financial news for ALXN dated on 2016-12-13: Benzinga's Top Upgrades, Downgrades For December 13, 2016

Financial news for ALXN dated on 2016-12-13: Morgan Stanley Downgrades Alexion Pharmaceuticals to Equal-Weight

Financial news for ALXN dated on 2016-12-12: Mid-Afternoon Market Update: Achaogen Surges On Positive Phase 3 Results; Alexion Shares Slide

Financial news for ALXN dated on 2016-12-12: 15 Biggest Mid-Day Losers For Monday

Financial news for ALXN dated on 2016-12-12: Mid-Day Market Update: Crude Oil Up Over 3%; Ophthotech Shares Tumble After Failed Phase 3 Trial Of Fovista

Financial news for ALXN dated on 2016-12-12: Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive

Financial news for ALXN dated on 2016-12-12: Mid-Morning Market Update: Markets Open Mixed; Crude Oil Hits 17-Month High On OPEC Commitments

Financial news for ALXN dated on 2016-12-12: Alexion Management Changes Overshadow Potentially Positive Audit Results

Financial news for ALXN dated on 2016-12-12: Alexion Pharmaceuticals Board Reportedly Lost Confidence In CEO And CFO

Financial news for ALXN dated on 2016-12-12: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for ALXN dated on 2016-12-12: UPDATE: Alexion Says At This Point In Time, The Audit and Finance Committee Has Not Identified Facts That Require The Co. To Update Previous Historical Results

Financial news for ALXN dated on 2016-12-12: Alexion Names David Brennan Interim CEO, David Anderson Joins As CFO; Expects To File Q3 10-Q In January

Financial news for ALXN dated on 2016-12-09: Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt

Financial news for ALXN dated on 2016-12-07: Why Stocks Move When Execs Cancel Presentation Appearances

Financial news for ALXN dated on 2016-12-07: Citi Global Healthcare Conf. Takes Place Today; Presenters Include Pfizer, Aerie Pharmaceuticals, Bristol-Myers, Alexion, Illumina, & Envision Healthcare

Financial news for ALXN dated on 2016-12-06: 8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting

Financial news for ALXN dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for ALXN dated on 2016-12-04: Alexion Announces New Data from ALXN1210 Dose-Escalation Study Show Rapid and Sustained Reductions in LDH in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH 2016

Financial news for ALXN dated on 2016-11-30: Watch These 7 Huge Call Purchases In Wednesday Trade

Financial news for ALXN dated on 2016-11-29: Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares Tumble After Failed Drug Trial

Financial news for ALXN dated on 2016-11-29: Alexion Spikes to High of \$126.24 Following Earlier Call Activity

Financial news for ALXN dated on 2016-11-29: Option Alert: ALXN Fri 12/2 124 Calls (Wkly) Sweep: 500 @ ASK \$2.35: 1035 traded vs 7 OI: Earnings 2/2 Before Open (est) \$122.50 Ref

Financial news for ALXN dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for ALXN dated on 2016-11-29: The Market In 5 Minutes: OPEC, Tiffany's And More Theranos Trouble

Financial news for ALXN dated on 2016-11-29: Benzinga's Top Upgrades

Financial news for ALXN dated on 2016-11-29: Barclays Upgrades Alexion Pharmaceuticals to Overweight

Financial news for ALXN dated on 2016-11-23: Alexion Shares Recently Turn Positive, Up ~2.5% from Session Lows

Financial news for ALXN dated on 2016-11-21: 10 Stocks That Rallied Four Days, Then Sold Off On Friday

Financial news for ALXN dated on 2016-11-21: BMO Sets Outperform Rating, \$26 Target On Ra Pharmaceuticals

Financial news for ALXN dated on 2016-11-21: Alexion, JetBlue, Sothebys: Fast Money Picks For November 21

Financial news for ALXN dated on 2016-11-17: Alexion Releases Data On Soliris Showing It Reduces Risk Of Dialysis Post-Transplant

Financial news for ALXN dated on 2016-11-16: Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q

Financial news for ALXN dated on 2016-11-15: Alexion's Valuation Could Be Getting Pummeled Unnecessarily

Financial news for ALXN dated on 2016-11-15: Shkreli's Very Bullish Call On Alexion Following Recent Downside: 'Double From Here'

Financial news for ALXN dated on 2016-11-14: Reminder: Alexion Pharmaceuticals Q3 10-Q Filing Extension Expires Today

Financial news for ALXN dated on 2016-11-11: UPDATE: Citigroup Doubts Alexion Soliris Problems Are Big Enough To Warrant The Selloff, Says Buy The Weakness, Maintains Buy And \$175 PT

Financial news for ALXN dated on 2016-11-11: Hearing Citi Issuing Mid-Day Defense on Alexion

Financial news for ALXN dated on 2016-11-11: UPDATE: Alexion Says 'Additional Long-Term Data Show Rapid and Sustained Reduction in ALT in 98% of Kanuma-Treated Patients at 76 Weeks'

Financial news for ALXN dated on 2016-11-11: Alexion Reports Long-Term Data in Liver Fibrosis, Cirrhosis Patients Using LAL-D Treated with Kanuma: Longer Duration of Kanuma Treatment Associated with Greater Reductions in Fibrosis Stage

Financial news for ALXN dated on 2016-11-10: Alexion Shares Plunge ~\$2 Over Last ~20 Mins, Down ~\$1 Over Last Few Mins

Financial news for ALXN dated on 2016-11-10: JPMorgan Believes Its Positive Long-Term Thesis On Alexion Remains Intact

Financial news for ALXN dated on 2016-11-10: Despite Alexion's Internal Investigation, Goldman Standing Behind Its Buy Rating

Financial news for ALXN dated on 2016-11-10: Alexion Management On Internal Investigation: So Far, So Good

Financial news for ALXN dated on 2016-11-10: Goldman Sachs Says Alexion Pharmaceuticals Buy Rating Predicated On Favorable Setup Heading Into FY17 As Co. Has Less U.S. Govt Exposure; However, SEC News Introduces Overhang And Looks For Additional Clarity In Coming Weeks

Financial news for ALXN dated on 2016-11-10: Credit Suisse Spoke With Alexion Pharma Mgmt, Does Not Believe Co Discovered Anything That Would Result In A Restatement Or Suggesting Wrongdoing, Maintains Outperform And \$165 PT

Financial news for ALXN dated on 2016-11-09: Alexion Shares Resume, Down ~4%

Financial news for ALXN dated on 2016-11-09: It's Official: Alexion's Q3 Filing Delayed Due To Internal Audit Investigation

Financial news for ALXN dated on 2016-11-09: Alexion Shares to Resume Trade at 5 p.m. EST

Financial news for ALXN dated on 2016-11-09: UPDATE: Alexion Says 'At this point in time...Committee's investigation has not identified instances where Soliris orders were not placed by customers for patients or any facts that require the Co. to update its previously reported historical results'

Financial news for ALXN dated on 2016-11-09: Alexion Pharma Down Over 6% After Hours; BZ NOTE: Shares Short Over Past 2 Weeks Have Decreased To 5,371,700M, Short Percent Of Float @ 2.41%

Financial news for ALXN dated on 2016-11-09: UPDATE: Alexion Says Has Retained Outside Counsel to Assist in Investigation, 'but at this time it is uncertain when this investigation will be complete and what the results of such investigation will be'

Financial news for ALXN dated on 2016-11-09: Alexion Says 10-Q Filing Delayed Due To Audit Committee Investigation Into Soliris Sales Practices Inconsistent With Company Policies

Financial news for ALXN dated on 2016-11-09: UPDATE: Alexion Cites 'conducting an investigation into allegations that recently have been made by a former employee with respect to the Company's Soliris sales practices.'

Financial news for ALXN dated on 2016-11-09: Alexion Pharma Delays 10-Q

Financial news for ALXN dated on 2016-11-09: Alexion Shares Halted News Pending

Financial news for ALXN dated on 2016-11-09: BZ NOTE: Deadline For Alexion Pharmaceuticals 10-Q will Be 5:30pm ET Today, Company Has Not Returned Multiple Calls and E-mails Made By Benzinga Newsdesk

Financial news for ALXN dated on 2016-11-09: Alexion Shares Moving Lower Over Last Few Mins as DJ Highlighting Chairman Bell Has Registered ~36.6K Shares

Financial news for ALXN dated on 2016-11-09: Watch These 7 Huge Put Purchases In Wednesday Trade

Financial news for ALXN dated on 2016-11-08: UPDATE: Citi Notes That They Last Connected With Alexion On Friday And Have Not Returned Our Emails Or Phone Calls

Financial news for ALXN dated on 2016-11-08: Citigroup Comments On Alexion, Says Co Either Files Tomorrow By 5:30pm EDT Or Files For Extension of Deadline By Thursday 5:30pm EDT, Maintains Buy & \$175 PT

Financial news for ALXN dated on 2016-11-08: UPDATE: Jefferies Comments on Gilead: 'ALXN's actions interpreted by some as suggesting they are in play.'; BZ NOTE: Note is Focused on Gilead, Not Necessarily Alexion; Jefferies Maintains Gilead is 'Undervalued'

Financial news for ALXN dated on 2016-11-08: UPDATE: Jefferies Note Highlighting Gilead for Alexion Titled 'Another Look At Our Hypothetical M&A Scenario Analysis'

Financial news for ALXN dated on 2016-11-08: Hearing Jefferies Defending Alexion, Says Gilead Could Buy Co.

Financial news for ALXN dated on 2016-11-08: Adam Feuerstein Tweets: \$ALXN continues to underperform on concerns about late 10-Q. "Something is definitely going on in New Haven," says Leerink's Geoff Porges.

Financial news for ALXN dated on 2016-11-08: dam Feuerstein @adamfeuerstein Tweet: \$ALXN continues to underperform on concerns about late 10-Q. "Something is definitely going on in New Haven," says Leerink's Geoff Porges

Financial news for ALXN dated on 2016-11-08: BZ NOTE: The Deadline for Alexion's 10-Q Filing (40 Days After the End of Last Qtr.) is Tomorrow, Wed., Nov. 9, 2016

Financial news for ALXN dated on 2016-11-08: UPDATE: Leerink on Alexion: Believes Recent Responses from Co. to Investor Inquiries Confirms View 'Something [Negative] is Definitely Going On'

Financial news for ALXN dated on 2016-11-08: Hearing Leerink Making a Negative Call on Alexion, Highlighting Delay in 10-Q Filing 11 Days After Q3 Report, No Disclosure in 8-K Suggests Range of Explanations Becoming Narrower

Financial news for ALXN dated on 2016-11-08: Option Alert: ALXN Fri 11/11 115 Puts (Wkly): 500 @ ASK \$5.00: 1437 traded vs 203 OI: Earnings 2/2 Before Open (est) \$118.21 Ref

Financial news for ALXN dated on 2016-11-07: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for ALXN dated on 2016-11-07: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for ALXN dated on 2016-11-04: Playing The Downside In Alexion Pharmaceuticals

Financial news for ALXN dated on 2016-11-04: Alexion Responding To Reports That Its Q3 10-Q Filing May Be Delayed Tells Benzinga The Company 'Continues To Finalize Our 10-Q In Accordance With Our Internal Processes'

Financial news for ALXN dated on 2016-11-04: Option Alert: ALXN Fri 12/23 134 Calls (Wkly) Sweep: 526 @ ASK \$11.10: 526 traded vs 0 OI: Earnings 2/2 Before Open (est) \$128.62 Ref

Financial news for ALXN dated on 2016-11-04: Alexion's Wild Friday: Rumors, Cancelled Conference Appearances And No 10Q Report Spur Volatility

Financial news for ALXN dated on 2016-11-04: TheStreet's Adam Feuerstein Recently Publishes 'Alexion Soars, Then Falls, Amid Takeover Rumors'

Financial news for ALXN dated on 2016-11-04: Citigroup Says Alexion Pharama DCF Valuation Range Is \$192-\$232, Maintains Buy And \$175 PT; BZ NOTE: Citi Note To

Clients Likely Published Prior To Report That Alexion May Delay Filing

Financial news for ALXN dated on 2016-11-04: Leerink Analyst Suggests Alexion Pharma Could Delay Its 10-Q Filing

Financial news for ALXN dated on 2016-11-04: Option Alert: ALXN Fri 11/11 130 Puts (Wkly): 1900 @ Above Ask! \$4.00: 1911 traded vs 58 OI: Earnings 2/2 Before Open (est) \$137.00 Ref

Financial news for ALXN dated on 2016-11-04: Hearing Alexion Has Said Mgmt Will Not Participate in Credit Suisse's Healthcare Conference on Nov. 7

Financial news for ALXN dated on 2016-11-04: Alexion, BioMarin Spike Higher as Traders Circulate Unconfirmed Report Alexion has Cancelled Out of CS Conference

Financial news for ALXN dated on 2016-11-04: Alexion Spikes to High of \$141.85 on Volume

Financial news for ALXN dated on 2016-11-03: Benzinga's Top Initiations

Financial news for ALXN dated on 2016-11-03: Deutsche Bank Initiates Coverage On Alexion Pharmaceuticals, Inc. - Common Stock at Buy

Financial news for ALXN dated on 2016-10-28: FBR Capital Upgrades Alexion Pharmaceuticals, Inc. - Common Stock to Market Perform

Financial news for ALXN dated on 2016-10-27: Alexion Sees FY EPS \$4.50 to \$4.65 Est, Revenue \$3.05B to \$3.10B Est

Financial news for ALXN dated on 2016-10-27: Alexion Q3 EPS \$1.08 vs \$1.17 Est, Revenue \$799M vs \$787M Est

Financial news for ALXN dated on 2016-10-27: Alexion Initiates Registration Trials of ALXN1210

Financial news for ALXN dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for ALXN dated on 2016-10-19: Alexion Reports The FDA Grants Orphan Drug Designation To ALXN1007

Financial news for ALXN dated on 2016-10-06: Alexion Reports Long-Term Data on Kanuma for LAL-D: 'Achieved Rapid and Sustained Reduction in ALT...in 97% of Kanuma-Treated Patients with LAL-D'

Financial news for ALXN dated on 2016-10-04: Benzinga's Top Initiations

Financial news for ALXN dated on 2016-10-04: The Market In 5 Minutes: A Three-Decade Low For The Pound

Financial news for ALXN dated on 2016-10-04: Brean Capital Assumes Alexion Pharmaceuticals at Buy, Announces \$221.00 PT

Financial news for ALXN dated on 2016-09-22: Wedbush Initiates Coverage on Alexion Pharmaceuticals at Neutral, Announces \$132.00 PT

Financial news for ALXN dated on 2016-09-15: FBR Capital Initiates Coverage on Alexion Pharmaceuticals at Underperform

Financial news for ALXN dated on 2016-08-29: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease

Financial news for ALXN dated on 2016-08-26: Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd

Financial news for ALXN dated on 2016-08-08: Alexion Says FDA Recently Completed Routine Current Good Manufacturing Practice Inspection of Alexion's Smithfield, RI Manufacturing Facility -8K

Financial news for ALXN dated on 2016-07-28: Short-Sellers Favor These 2 Biotech Stocks In July

Financial news for ALXN dated on 2016-07-28: Alexion Reaffirms FY16 Sales Outlook \$3.05B-\$3.1B, EPS \$4.50-\$4.65

Financial news for ALXN dated on 2016-07-28: Alexion Pharma Reports Adj. EPS \$1.13, Sales \$753M vs \$636M in Same Qtr. Last Year

Financial news for ALXN dated on 2016-07-28: Earnings Scheduled For July 28, 2016



Financial news for ALXN dated on 2016-07-14: 5 Stocks With Potential To Rally 12% Or More, According To Analysts

Financial news for ALXN dated on 2016-07-14: Alexion Pharma Says Prelim. SBC-103 Phase 1/2 Data on Brain MRI, Neurocognitive Assessments Shows Potential for Dose-Dependent Disease in MPS IIIB Patients

Financial news for ALXN dated on 2016-07-13: RBC Capital Initiates Coverage on Alexion Pharmaceuticals at Outperform

Financial news for ALXN dated on 2016-07-11: 7 Largest Price Target Changes For Monday

Financial news for ALXN dated on 2016-07-11: Benzinga's Top Upgrades

Financial news for ALXN dated on 2016-07-11: Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating

Financial news for ALXN dated on 2016-07-11: Upside Surprises More Likely Than Downside for Alexion Pharmaceuticals, Says Credit Suisse

Financial news for ALXN dated on 2016-07-11: Credit Suisse Upgrades Alexion Pharmaceuticals to Outperform, Lowers PT to \$165.00

Financial news for ALXN dated on 2016-07-07: New Data from Phase 3 REGAIN Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress

Financial news for ALXN dated on 2016-06-29: 9 Stocks Haunted By Brexit, Creating Unwarranted Drops

Financial news for ALXN dated on 2016-06-27: Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation

Financial news for ALXN dated on 2016-06-27: Benzinga's Top Upgrades

Financial news for ALXN dated on 2016-06-27: Citigroup Upgrades Alexion Pharmaceuticals from Neutral to Buy

Financial news for ALXN dated on 2016-06-20: Martin Shkreli @MartinShkreli Tweet: \$ALXN probably worth 50-100% more than current share price indicates.

Financial news for ALXN dated on 2016-06-10: Alexion Pharmaceuticals Announces All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH in Late-Breaking Data Presented at EHA:

Financial news for ALXN dated on 2016-06-07: Alexion Closed Down 10%; Piper Says 'Buy On Weakness'

Financial news for ALXN dated on 2016-06-07: Barclays Cuts Alexion Pharmaceuticals Target From \$180 To \$165

Financial news for ALXN dated on 2016-06-07: 8 Biggest Mid-Day Losers For Tuesday

Financial news for ALXN dated on 2016-06-07: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALXN dated on 2016-06-06: 4 Stocks Moving In Monday's After-Hours Session

Financial news for ALXN dated on 2016-06-06: Alexion Shares Fall To Low Of \$140 After Hours After Being Halted

Financial news for ALXN dated on 2016-06-06: UPDATE: Alexion Says Primary Endpoint of REGAIN Study Missed Statistical Significance

Financial news for ALXN dated on 2016-06-06: Alexion Reports Topline Results from Phase 3 REGAIN Study of Soliris in Patients with gMG

Financial news for ALXN dated on 2016-06-06: Alexion Pharma Shares Halted News Pending

Financial news for ALXN dated on 2016-06-03: Cantor Fitzgerald Starts Omeros With Buy, \$21PT

Financial news for ALXN dated on 2016-06-01: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria, exceeded target enrollment

Financial news for ALXN dated on 2016-05-17: Has A Biotech Recovery Started Yet?

Financial news for ALXN dated on 2016-04-29: BMO Capital Upgrades Alexion Pharmaceuticals to Outperform

Financial news for ALXN dated on 2016-04-28: Short Sellers Dump Vertex, Load Up On Baxalta

Financial news for ALXN dated on 2016-04-28: 12 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALXN dated on 2016-04-12: After-Hours Recap: Medivation, Valeant, CSX & More

Financial news for ALXN dated on 2016-04-07: After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More

Financial news for ALXN dated on 2016-04-07: BMO Capital Initiates Coverage on Alexion Pharmaceuticals at Market Perform

Financial news for ALXN dated on 2016-04-04: Alexion Pharma Reports Data Presented at ENDO '16 Showed Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support, Physical Function in Children with HPP Receivingin Strensiq

Financial news for ALXN dated on 2016-03-28: Alexion Pharma Drug Kanuma Recieves Marketing Approval in Japan for Lysosomal Acid Lipase Deficiency

Financial news for ALXN dated on 2016-03-14: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for ALXN dated on 2016-03-10: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for ALXN dated on 2016-03-07: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for ALXN dated on 2016-03-07: Baird Downgrades Alexion Pharmaceuticals to Neutral, Lowers PT to \$170.00

Financial news for ALXN dated on 2016-03-03: The Stocks That Moved The S&P, Dow And Nasdaq Today

Financial news for ALXN dated on 2016-03-03: Ensemble Therapeutics Announces Early-Stage Research Milestone In Its Drug Discovery Partnership With Alexion Pharmaceuticals